Search Result

Results for "

CYP17A1 Inhibitors

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Androgen Receptor (3) Cytochrome P450 (15) Drug Metabolite (5) HDAC (1) Isotope-Labeled Compounds (2)
By Research Areas:	Cancer (19) Metabolic Disease (1)

Inhibitors & Agonists

Isotope-Labeled Compounds

Targets Recommended: Serpin

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-148375

Abiraterone sulfate	Drug Metabolite	Others
Abiraterone sulfate is a metabolite of Abiraterone (HY-148377). Abiraterone is a potent and irreversible CYP17A1 inhibitor with antiandrogen activity .

HY-75054

Abiraterone acetate Maximum Cited Publications 19 Publications Verification CB7630	Cytochrome P450	Cancer
Abiraterone acetate (CB7630) is an oral, potent, selective, and irreversible inhibitor of *CYP17A1* with antiandrogen activity. Abiraterone acetate is a proagent form of Abiraterone (CB7598).

HY-172173

CYP17A1-IN-1	Cytochrome P450	Cancer
CYP17A1-IN-1 (Compound 14) is the inhibitor for *CYP17A1* with an IC₅₀ of 26 nM. CYP17A1-IN-1 exhibits cytotoxicity in androgen-sensitive prostate cancer cell LNCaP, inhibits the migration of cell DU-145 .

HY-163359

CYP17A1/HDAC6-IN-1	Cytochrome P450 HDAC	Cancer
CYP17A1/HDAC6-IN-1 (compound 12) is a potent inhibitor of CYP17A1/HDAC6, with IC₅₀ of 0.284μM and 0.6015 μM,respectively. CYP17A1/HDAC6-IN-1 has anti-tumor activity .

HY-117529

BMS-351	Cytochrome P450	Cancer
BMS-351 (compound 18) is a potent, oral active, nonsteroidal CYP17A1 lyase inhibitor with the IC₅₀ values of 19 nM and 4 nM aganist human CYP17A1 and cynomolgus monkeys CYP17A1,respectively. BMS-351 can be used for the study of castration-resistant prostate cancer .

HY-116643

SU 10603	Cytochrome P450	Metabolic Disease
SU 10603 is a specific inhibitor of P45017α (P450c17; CYP17A1) .

HY-148376

Abiraterone N-oxide	Drug Metabolite	Cancer
Abiraterone N-oxide is a metabolite of Abiraterone (HY-148377). Abiraterone is a potent and irreversible CYP17A1 inhibitor with antiandrogen activity .

HY-155666

YXG-158	Androgen Receptor	Cancer
YXG-158 (Compound 23-h) is an orally active AR degrader and *CYP17A1* inhibitor. YXG-158 has AR degradation activity with DC₅₀ value of 1.28 μM. YXG-158 can inhibit CYP17A1 with IC₅₀ value of 100 nM. XG-158 can be used for the research of enzalutamide-resistant prostate cancer .

HY-164457

ASN-001	Cytochrome P450	Cancer
ASN-001 is an orally active *CYP-17A1* lyase inhibitor that selectively inhibits testosterone synthesis. ASN-001 has anticancer activity and can be used for research in the field of prostate cancer .

HY-111421

ODM-204	Androgen Receptor Cytochrome P450	Cancer
ODM-204 is novel nonsteroidal dual inhibitor of both androgen receptor and CYP17A1 enzyme, with IC₅₀s of 80 nM and 22 nM, respectively.

HY-103687

Abiraterone metabolite 1 3β-OH-5α-Abi	Drug Metabolite	Cancer
Abiraterone metabolite 1 is a 5β-reduced metabolite of abiraterone. Abiraterone, a steroidal agent, inhibits CYP17A1, blocks androgen synthesis and prolongs survival in prostate cancer.

HY-137389

Anhydro abiraterone	Drug Metabolite	Cancer
Anhydro abiraterone is a degradation product of Abiraterone acetate (HY-75054). Abiraterone acetate (CB7630) is an oral, potent, selective, and irreversible inhibitor of CYP17A1 with antiandrogen activity .

HY-75054S

Abiraterone acetate-d4 CB7630-d₄	Isotope-Labeled Compounds Cytochrome P450	Cancer
Abiraterone acetate-d₄ is the deuterium labeled Abiraterone acetate. Abiraterone acetate (CB7630) is an oral, potent, selective, and irreversible inhibitor of CYP17A1 with antiandrogen activity. Abiraterone acetate is a proagent form of Abiraterone (CB7598).

HY-137193

5,6-Dihydroabiraterone	Drug Metabolite	Cancer
5,6-Dihydroabiraterone is the metabolism of Abiraterone (HY-70013). Abiraterone is a potent and irreversible CYP17A1 inhibitor with antiandrogen activity, and shows antitumor activity in CRPC (castration-resistant prostate cancer) .

HY-75054R

Abiraterone acetate (Standard) Maximum Cited Publications 19 Publications Verification CB7630 (Standard)	Cytochrome P450	Cancer
Abiraterone acetate (Standard) is the analytical standard of Abiraterone acetate. This product is intended for research and analytical applications. Abiraterone acetate (CB7630) is an oral, potent, selective, and irreversible inhibitor of *CYP17A1* with antiandrogen activity. Abiraterone acetate is a proagent form of Abiraterone (CB7598).

HY-70013

Abiraterone Maximum Cited Publications 19 Publications Verification CB-7598	Cytochrome P450	Cancer
Abiraterone is a potent and irreversible *CYP17A1* inhibitor with antiandrogen activity, which inhibits both the 17α-hydroxylase and 17,20-lyase activity of the cytochrome p450 enzyme CYP17 with IC₅₀s of 2.5 nM and 15 nM, respectively.

HY-109619

D4-abiraterone Δ4-Abiraterone; CB-7627; Abiraterone D4A metabolite	Androgen Receptor Cytochrome P450	Cancer
D4-abiraterone is a major metabolite of abiraterone. D4-abiraterone is an inhibitor of *CYP17A1, 3b-hydroxysteroid dehydrogenase (3βHSD) and steroid-5a-reductase (SRD5A) and also an antagonist of androgen receptor*.

HY-75054S1

Abiraterone acetate-d3 CB7630-d₃	Isotope-Labeled Compounds Cytochrome P450	Cancer
Abiraterone acetate-d₃ (CB7630-d₃) is deuterium labeled Abiraterone acetate. Abiraterone acetate (CB7630) is an oral, potent, selective, and irreversible inhibitor of *CYP17A1* with antiandrogen activity. Abiraterone acetate is a proagent form of Abiraterone (CB7598) .

HY-70013S

Abiraterone-d4 CB-7598-d₄	Cytochrome P450	Cancer
Abiraterone-d₄ is the deuterium labeled Abiraterone. Abiraterone is a potent and irreversible CYP17A1 inhibitor with antiandrogen activity, which inhibits both the 17α-hydroxylase and 17,20-lyase activity of the cytochrome p450 enzyme CYP17 with IC50s of 2.5 nM and 15 nM, respectively.

HY-70013R

Abiraterone (Standard)	Cytochrome P450	Cancer
Abiraterone (Standard) is the analytical standard of Abiraterone. This product is intended for research and analytical applications. Abiraterone is a potent and irreversible *CYP17A1* inhibitor with antiandrogen activity, which inhibits both the 17α-hydroxylase and 17,20-lyase activity of the cytochrome p450 enzyme CYP17 with IC₅₀s of 2.5 nM and 15 nM, respectively.

HY-101516

CYP17-IN-1	Cytochrome P450	Cancer
CYP17-IN-1 (compound 9c) is a potent and orally active *CYP17* inhibitor against rat and human CYP17 with IC₅₀s of 15.8 and 20.1 nM .

Cat. No.	Product Name	Chemical Structure

HY-70013S

Abiraterone-d4
Abiraterone-d₄ is the deuterium labeled Abiraterone. Abiraterone is a potent and irreversible CYP17A1 inhibitor with antiandrogen activity, which inhibits both the 17α-hydroxylase and 17,20-lyase activity of the cytochrome p450 enzyme CYP17 with IC50s of 2.5 nM and 15 nM, respectively.

HY-75054S

Abiraterone acetate-d4
Abiraterone acetate-d₄ is the deuterium labeled Abiraterone acetate. Abiraterone acetate (CB7630) is an oral, potent, selective, and irreversible inhibitor of CYP17A1 with antiandrogen activity. Abiraterone acetate is a proagent form of Abiraterone (CB7598).

HY-75054S1

Abiraterone acetate-d3
Abiraterone acetate-d₃ (CB7630-d₃) is deuterium labeled Abiraterone acetate. Abiraterone acetate (CB7630) is an oral, potent, selective, and irreversible inhibitor of *CYP17A1* with antiandrogen activity. Abiraterone acetate is a proagent form of Abiraterone (CB7598) .

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

Name
Email *

	Sorry, but the email address you supplied was invalid.